Massachusetts Society of Clinical Oncologists - FDA Approves acalabrutinib (Calquence) for CLL and SLL

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
FDA Approvals
FDA Approves acalabrutinib (Calquence) for CLL and SLL

FDA Approves acalabrutinib (Calquence) for CLL and SLL

21 Nov 2019 2:57 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved acalabrutinib (Calquence; AstraZeneca) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org